{"id":3685,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1999-07-23","marketCap":14387.2,"name":"Biomarin Pharmaceutical Inc","phone":"14155066700","outstanding":189.88,"symbol":"BMRN","website":"https://www.biomarin.com/","industry":"Biotechnology"},"price":74.6575,"year":2024,"month":5,"day":31,"weekday":"Friday","title":"Historical Revenue Growth Trends of Biomarin Pharmaceutical Inc","date":"2024-05-31","url":"/posts/2024/05/31/BMRN","content":[{"section":"Year 2016: Declining Revenue","text":"In 2016, Biomarin Pharmaceutical Inc reported a revenue of $1.11 billion, representing a decrease of 8% compared to the previous year. This decline in revenue can be attributed to several factors, including the loss of exclusivity for some of its key products and lower sales volumes."},{"section":"Year 2017: Strong Recovery","text":"The company experienced a significant rebound in 2017, with its revenue increasing by 18% to reach $1.31 billion. This growth was primarily driven by the strong sales performance of its rare disease therapies, such as Vimizim and Kuvan. The successful launch of new products also contributed to the revenue growth."},{"section":"Year 2018: Continuous Growth","text":"Biomarin Pharmaceutical Inc continued its growth momentum in 2018, reporting a revenue of $1.49 billion, reflecting a growth rate of 14%. The company's core products, including Naglazyme and Brineura, continued to generate substantial sales. Additionally, the expansion of its product portfolio and successful clinical trials further supported the revenue growth."},{"section":"Year 2019: Modest Growth","text":"In 2019, Biomarin Pharmaceutical Inc recorded a revenue of $1.66 billion, representing a modest growth rate of 11%. The company faced some challenges, such as increased competition and pricing pressures, which impacted its revenue growth. However, the strong performance of its gene therapy portfolio, including Valoctocogene Roxaparvovec, contributed to overall revenue growth."},{"section":"Year 2020: Pandemic Impact","text":"The COVID-19 pandemic had a mixed impact on Biomarin Pharmaceutical Inc's revenue growth in 2020. The company reported a revenue of $1.73 billion, indicating a growth rate of 4%. While the pandemic led to disruptions in the healthcare system and reduced patient visits, the demand for the company's rare disease therapies remained relatively stable. Furthermore, the successful launch of Palynziq contributed to revenue growth."},{"section":"Implications for Investors","text":"The historical revenue growth trends of Biomarin Pharmaceutical Inc indicate a mixed performance. While the company faced challenges in certain years, it demonstrated the ability to recover and sustain growth, driven by its strong product portfolio and successful launches. Investors should consider the company's efforts in developing innovative therapies for rare diseases and the potential for revenue growth through new product launches and clinical trial results. However, they should also pay attention to factors such as competition, pricing pressures, and the potential impact of external events on the company's performance."}],"tags":["OverSold","Long","Biotechnology"],"news":[{"category":"company","date":1717016058,"headline":"Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2024 Update","id":127963266,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/200502280/image_200502280.jpg?io=getty-c-w1536","symbol":"BMRN","publisher":"SeekingAlpha","summary":"Discover the latest updates on Ole Andreas Halvorsen's 13F stock portfolio in Q1 2024, including its value, number of holdings, and top individual. Read more here.","url":"https://seekingalpha.com/article/4696332-tracking-ole-andreas-halvorsens-viking-global-portfolio-q1-2024-update"},{"category":"company","date":1716875040,"headline":"BridgeBio price target lowered by $4 at UBS, here's why","id":127934477,"image":"","symbol":"BMRN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3515062130"},{"category":"company","date":1716858300,"headline":"Looking Into Biomarin Pharmaceutical's Recent Short Interest","id":127936868,"image":"","symbol":"BMRN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3515561496"},{"category":"company","date":1716809177,"headline":"BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders have endured a 15% loss from investing in the stock a year ago","id":127922628,"image":"https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","symbol":"BMRN","publisher":"Yahoo","summary":"It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...","url":"https://finance.yahoo.com/news/biomarin-pharmaceutical-nasdaq-bmrn-shareholders-112617997.html"},{"category":"company","date":1716711000,"headline":"Parnassus  Mid Cap Growth Fund Q1 2024 Investment Commentary","id":127912304,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1417583870/image_1417583870.jpg?io=getty-c-w1536","symbol":"BMRN","publisher":"SeekingAlpha","summary":"Parnassus Mid Cap Growth Fund returned 7.85% for Q1 2024, underperforming the Russell Midcap Growth Indexâs 9.50% return. Click here to read more.","url":"https://seekingalpha.com/article/4695713-parnassus-mid-cap-growth-fund-q1-2024-investment-commentary"},{"category":"company","date":1716701400,"headline":"Parnassus Value Equity Fund Q1 2024 Investment Commentary","id":127910903,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2043585151/image_2043585151.jpg?io=getty-c-w1536","symbol":"BMRN","publisher":"SeekingAlpha","summary":"The Parnassus Value Equity Fund returned 10.17%, better than the Russell 1000 Valueâs 8.99% in Q1 2024. Click here to read the full letter.","url":"https://seekingalpha.com/article/4695697-parnassus-value-equity-fund-q1-2024-investment-commentary"},{"category":"company","date":1716564666,"headline":"BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound?","id":127899612,"image":"https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f","symbol":"BMRN","publisher":"Yahoo","summary":"BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","url":"https://finance.yahoo.com/news/biomarin-bmrn-down-7-6-153106981.html"},{"category":"company","date":1716456000,"headline":"Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and BioMarin Pharmaceutical (BMRN)","id":127865359,"image":"","symbol":"BMRN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3509120046"},{"category":"company","date":1716099780,"headline":"Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)","id":127797317,"image":"","symbol":"BMRN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3503383723"},{"category":"company","date":1716023160,"headline":"4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market","id":127773870,"image":"https://g.foolcdn.com/editorial/images/777543/bull-market-rising-stock-charts-financial-newspaper-quotes-invest-getty.jpg","symbol":"BMRN","publisher":"Yahoo","summary":"Plain-as-day bargains can still be found, even with the innovation-fueled Nasdaq Composite powering to a fresh all-time high.","url":"https://www.fool.com/investing/2024/05/18/nasdaq-bull-market-4-growth-stocks-regret-not-buy/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1715943060,"headline":"What You Missed On Wall Street This Morning","id":127756899,"image":"","symbol":"BMRN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500651475"},{"category":"company","date":1715935140,"headline":"Robinhood upgraded, Baidu downgraded: Wall Street's top analyst calls","id":127756900,"image":"","symbol":"BMRN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500498085"},{"category":"company","date":1715928300,"headline":"Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday","id":127757039,"image":"","symbol":"BMRN","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500380499"},{"category":"company","date":1715919720,"headline":"Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS)","id":127761060,"image":"","symbol":"BMRN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500256213"},{"category":"company","date":1715917680,"headline":"BioMarin just downgraded at Baird, here's why","id":127764754,"image":"","symbol":"BMRN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500230445"},{"category":"company","date":1715916960,"headline":"Hold Rating on BioMarin Amid Competitive Pressures and Growth Concerns","id":127764755,"image":"","symbol":"BMRN","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500221038"},{"category":"company","date":1715915460,"headline":"What You Missed On Wall Street On Friday","id":127764756,"image":"","symbol":"BMRN","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3500978395"}]}